Evaluation of pathways involved in the protective effect of trans sodium crocetinate against contrast-induced nephropathy in rats.

Contrast-induced nephropathy (CIN) is the most important side effect following contrast media application. The purpose of this study was to investigate the nephroprotective effects of trans sodium crocetinate (TSC) against sodium amidotrizoate/meglumine amidotrizoate (SAMA). Wistar rats were classified into eight groups (n = 6, male, 220-250 g) including (1) sham, injection of solvents (intraperitoneally; i.p.), (2) premedication-control, N(ω)-nitro-L-arginine methyl ester (L-NAME, 10 mg/kg, i.p.) + indomethacin (IND, 10 mg/kg, i.p.), (3) model (L-NAME + IND + SAMA (12.5 ml/kg, i.p.)), (4-6) TSC 10, 20, and 40 mg/kg/day, 7 days, i.p., and L-NAME + IND + SAMA, (7) N-acetylcysteine (NAC, 125 mg/kg/day, 7 days, i.p.) and L-NAME + IND + SAMA, (8) TSC alone (40 mg/kg/day, 7 days, i.p.). Rats were injected with L-NAME, IND, and SAMA 40 h after water deprivation. SAMA caused the enhancement of histopathological damage in kidney tissue, biochemical factors (serum blood urea nitrogen and creatinine), and oxidative stress. Moreover, SAMA increased inflammation (TNF-α), apoptosis proteins (Caspase 3-cleaved and Bax/Bcl-2 ratio), and autophagy markers (Beclin-1 and LC3 II/I ratio). TSC declined biochemical factors and oxidative stress. Also, TSC 40 mg/kg decreased histopathological damage, inflammation, apoptosis, and autophagy markers. This study demonstrated that TSC has nephroprotective effects through anti-oxidant, anti-inflammatory, and anti-apoptotic properties, as well as regulating autophagy.